Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DRIHNC - Dehydration Reduction in Head & Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03799380
Recruitment Status : Completed
First Posted : January 10, 2019
Last Update Posted : November 3, 2021
Sponsor:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:
The purpose of this study is to decrease the rate of visits to the Emergency Department (ED) and Acute Care Clinics (ACC) for dehydration for head & neck (H&N) and esophageal cancer patients that are given Gatorade while receiving radiation therapy with or without chemotherapy.

Condition or disease Intervention/treatment Phase
Dehydration Head & Neck Cancer Esophageal Cancer Dietary Supplement: Gatorade G2 Dietary Supplement: Standard of care nutritional support Not Applicable

Detailed Description:

Among patients with cancer of the H&N or esophagus, complications related to dehydration are fairly common, and can result in requiring IV fluid support in an ACC setting, ED or even inpatient admission. By instructing participants to drink a reasonable amount of a common electrolyte-rich energy drink from the initiation of treatment through its completion, the hypothesis will be tested that this inexpensive and easily administered preventative strategy can significantly decrease the rate of ACC and ED visits.

The objectives of this study are to decrease the frequency of ACC visits during the course of radiation therapy and decrease the frequency of ED visits during the course of radiation therapy. The study team also seeks to decrease the incidence of orthostatic vital signs during the course of radiation therapy and decrease the number of days of missed treatments due to radiation toxicity during the course of radiation therapy.

In the pilot cohort, participants will be given Gatorade G2 to drink daily during the course of radiation, along with standard of care nutritional support from dietitians. The randomized Phase 2 cohort has two study groups. Group 1 will receive standard of care nutritional support. Group 2 will receive standard of care nutritional support plus the study agent, Gatorade G2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: DRIHNC - Dehydration Reduction in Head & Neck Cancer: Daily Oral Fluid and Electrolyte Maintenance to Prevent Acute Care Clinic and Emergency Department Visits for Patients Receiving Radiation With or Without Chemotherapy/Immunotherapy for Head & Neck and Esophageal Cancer.
Actual Study Start Date : November 5, 2019
Actual Primary Completion Date : May 5, 2021
Actual Study Completion Date : May 5, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Control - Standard of Care
Standard of care nutritional support
Dietary Supplement: Standard of care nutritional support
Standard of care nutritional support

Experimental: Experimental - Gatorade
Standard of care nutritional support with the addition of daily Gatorade G2
Dietary Supplement: Gatorade G2
Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)




Primary Outcome Measures :
  1. ACC visits [ Time Frame: Up to 11 weeks after start of treatment ]
    ACC visits during the course of radiation (7 weeks). Participants are followed for 4 weeks after completion of radiation.

  2. ED visits [ Time Frame: Up to 11 weeks after start of treatment ]
    Number of ED visits during the course of radiation (7 weeks). Participants are followed for 4 weeks after completion of radiation.


Secondary Outcome Measures :
  1. Incidence of orthostatic vital signs [ Time Frame: Up to 11 weeks after start of treatment ]
    Number of orthostatic vital signs during the course of radiation therapy assessed at weekly visits.

  2. Missed days of radiation +/- chemotherapy/immunotherapy treatment [ Time Frame: Up to 7 weeks after start of treatment ]
    Number of missed days of radiation treatment among H&N and esophageal cancer patients undergoing radiation +/- chemotherapy/immunotherapy during the course of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Subjects must have histologically confirmed primary invasive cancer of the H&N (Nasopharynx/Nasal Cavity, Oral cavity, Oropharynx, Larynx, Hypopharynx) or Esophagus.

Histologies: squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma Stages: Any stage that necessitates radiation therapy (either definitive, neoadjuvant or adjuvant) as per standard practice guidelines (NCCN, ASTRO)

  • Subjects must have received no prior radiation therapy to the head, neck, thorax or abdomen in the last 1 year (with the exception of scalp squamous cell or basal cell carcinoma.
  • ECOG Performance status 0-2.
  • Life expectancy of ≥ 3 months, in the opinion of and as documented by the investigator.
  • Subjects must have organ and marrow function based on lab values deemed acceptable to proceed with radiation therapy. No additional or specific lab value cutoffs are required for this protocol given the nature of the intervention. General guidelines are provided below.
  • Hemoglobin ≥ 7 g/dl
  • Absolute neutrophil count ≥ 500/mcL
  • Platelet count ≥ 50,000/mcL
  • Total bilirubin within normal institutional limits
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.
  • HIV-positive subjects on combination antiretroviral therapy are eligible.

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment.

  • Prior radiation therapy to the head, neck, thorax or abdomen in the last year, with the exception of scalp squamous cell or basal cell carcinoma.
  • Patients with active, uncontrolled, symptomatic volume overload congestive heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03799380


Locations
Layout table for location information
United States, Ohio
Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Elisha Fredman, MD University Hospitals Cleveland Medical Center
Layout table for additonal information
Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03799380    
Other Study ID Numbers: CASE8318
First Posted: January 10, 2019    Key Record Dates
Last Update Posted: November 3, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Esophageal Neoplasms
Dehydration
Neoplasms by Site
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Water-Electrolyte Imbalance
Metabolic Diseases
Pathologic Processes